FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated Jun 2, 2015

MYO-DEN Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1715-2015

Class II · Moderate risk Terminated Jun 2, 2015

Myers Cocktail Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1714-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 60 mg/ml + Fentanyl 12

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1713-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Fentanyl 20

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1712-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Ropivacaine 5 mg/ml +Baclofen 20 mcg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1711-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Fentanyl 3

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1710-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Fentanyl 3

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1709-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Fentanyl 2

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1708-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Fentanyl 10

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1707-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Fentanyl 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1706-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Clonidine 750 mcg/ml + Baclofen 15 mcg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1705-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 50 mg/ml + Clonidine 500 mcg/ml +Bupivacaine 2.5 mg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1704-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 45 mg/ml + Bupivacaine 8 mg/ml + Baclofen 25 mcg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1703-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 25 mg/ml + Bupivacaine 30 mg/ml + Clonidine 200 mcg/ml Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1702-2015

Class II · Moderate risk Terminated Jun 2, 2015

Morphine 25 mg/ml + Bupivacaine 20 mg/ml + Clonidine 2

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1701-2015

Class II · Moderate risk Terminated Jun 2, 2015

MEGA-BURN* Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1700-2015

Class II · Moderate risk Terminated Jun 2, 2015

MEGA-BURN III Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1699-2015

Class II · Moderate risk Terminated Jun 2, 2015

MEGA-BURN IV Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1698-2015

Class II · Moderate risk Terminated Jun 2, 2015

MEGA-BURN Injectable ROCK CREEK

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1697-2015

Class II · Moderate risk Terminated Jun 2, 2015

MEGA-BURN Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1696-2015

Class II · Moderate risk Terminated Jun 2, 2015

Lipovicine-Choline 100 mg/ml-Acorbic Acid 45 mg/ml Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1695-2015

Class II · Moderate risk Terminated Jun 2, 2015

Lipovicine Modified II Injectable

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1694-2015

Class II · Moderate risk Terminated Jun 2, 2015

Lipotropic Methyl B-12 Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1693-2015

Class II · Moderate risk Terminated Jun 2, 2015

Lipotropic B-12 II* + Lidocaine Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1692-2015

Class II · Moderate risk Terminated Jun 2, 2015

Lipotropic B-12 Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1691-2015